The survey, which was released on Thursday (5 November) by the market research company Ipsos in conjunction with the World Economic Forum, found there is a growing reluctance to receive a vaccine, with a decline in vaccine intent found in 10 of the 15 countries surveyed.
The survey also asked how soon after a vaccine becomes available people would be willing to get one.
Amid rising coronavirus cases in India, Dr Randeep Guleria, director of AIIMS and member of the national task force on COVID-19 management, has said that common Indians will have to wait till 2022 to get COVID-19 vaccine.
As per the survey, 73 percent of adults across the globe said they intend to get a COVID-19 vaccine if available.
The number has dropped 4 per cent as compared to a similar survey conducted by WEF and Ipsos three months ago in which 77 per cent of adults had said that they were willing to take a vaccine when available. "So if we have a vaccine that comes out later and is seen to be more effective than the first one, how do we position it?" 34 per cent of the people surveyed expressed vaccine confidence concerns are around side effects.
Apart from this, 10 per cent of people cited the reason that the vaccine is unlikely to be effective while 10 per cent of participants were against vaccines in general.
Drilon had earlier prodded the government to participate in bilateral and multilateral efforts to secure immediate access to vaccines.
Japan and China reported the highest level of concern about side effects, while worry over the hastiness with which trails are being conducted was highest in Brazil and Spain.
Concern about side effects was highest in Japan (62 per cent) and China (46 per cent). General opposition to vaccines was highest in South Africa (21 per cent) and India (19 per cent).
The health expert added that it is critical that governments and the private sector work to build trust in the next steps.
COVID19 vaccine Sputnik V was registered on August 11. It was conveyed that the MEA would organise a tour for heads of diplomatic missions and global organisations to Pune where they can visit institutions engaged in coronavirus research and vaccine development programmes, a MEA statement said.
Australia has now lined up a total of 134 million doses across four vaccine candidates, with today's announcement following agreements made in September with the University of Oxford / AstraZeneca (for 33.8 million doses) and Australia's University of Queensland / CSL (51 million doses).
Indian firm Bharat Biotech, which is developing indigenous vaccine "COVAXIN" with the Indian Council of Medical Research (ICMR), is also expected to be launched by the beginning of next year.